Efficacy and Safety of Cyclosporine Microemulsion in Diabetic Adult Stable Liver Transplant Recipients
Phase 4
Completed
- Conditions
- Liver Transplant
- Registration Number
- NCT00171743
- Lead Sponsor
- Novartis
- Brief Summary
The purpose of this study is to determine whether the switch from tacrolimus to cyclosporine microemulsion benefits post-transplant diabetes management (in terms of glycogenic control and insulin dosage) in stable liver transplant recipients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 47
Inclusion Criteria
- At least 4 months post-transplant
- Patients in treatment with tacrolimus
- Post-transplant diabetes treated with insulin for at least one month
Exclusion Criteria
- Known hypersensitivity to cyclosporine microemulsion
- Investigational drug within 60 days before baseline or during the study
- Patients who cannot comply with the study requirements
Other protocol-defined exclusion criteria applied
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- FACTORIAL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method